-
Interpret the rhythm strip shown above. Does it represent 2nd degree AV block, Mobitz Type II? Can you be sure?
-
The first orally administered factor XA inhibitor has been approved by the FDA for the prevention of deep vein thrombosis (DVT). Rivaroxaban was developed by Bayer and is marketed in this country by Janssen Pharmaceuticals as Xarelto.
-
Clinical depression is highly prevalent in the general population and in primary care settings. Although clinicians presently have a broad array of pharmacological agents for the treatment of depression, including selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, overall response rates and remission rates with these pharmacological agents remain relatively modest.
-
-
The authors conducted a series of experiments in which HIV-1 transfected 1G5 T cells were exposed to either a series of known long terminal repeat (TLR) ligands (FimH/TLR-4, flagellin/TLR-5, and poly I:C/TLR-3) or STI pathogens (HSV-1, HSV-2, and N. gonorrhoeae).
-
A total of 130 singleton stillbirths from a single institution in Australia, from January 2005 through December 2006, of > 20 weeks gestation with no cause of death and with available formalin-fixed, paraffin-embedded tissues were examined by multiplex PCR for 19 infectious agents, and by immunohistochemistry for human cytomegalovirus (CMV).
-
In this issue: Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.
-
A 58-year-old Liberian-born woman was in excellent general health, living and working in a large academic medical center in Rhode Island for more than 20 years, when she developed nonspecific gastrointestinal symptoms and underwent endoscopy, which revealed Strongyloides stercoralis larvae on a duodenal biopsy in March 2010.
-
Oude Lashof and colleagues examined the incidence and outcomes of patients with ocular involvement in a randomized, clinical trial comparing treatment of non-neutropenic patients with candidemia with either voriconazole or amphotericin B followed by fluconazole.
-